Evidence map›Paper›PMID 37093796›Full record

ArticlePloS one2023

Comparison of new and emerging SARS-CoV-2 variant transmissibility through active contact testing. A comparative cross-sectional household seroprevalence study.

Katherine M Gaskell, Natalie El Kheir, Mariyam Mirfendesky, Tommy Rampling, Michael Marks, Catherine F Houlihan, Norbert Lemonge, Hannah Bristowe, Suhail Aslam, Demetra Kyprianou and 5 more

Abstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Katherine M GaskellClinical Research Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.ORCID 0000-0003-4691-6359
Natalie El KheirClinical Research Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Mariyam MirfendeskyNorth Middlesex University Hospital NHS Trust, London, United Kingdom.
Tommy RamplingHospital for Tropical Diseases, University College London Hospitals Foundation NHS Trust, London, United Kingdom.
Michael MarksDivision of Infection and Immunity, University College London, London, United Kingdom.
Catherine F HoulihanDepartment of Clinical Virology, University College London Hospitals Foundation NHS Trust, London, United Kingdom.
Norbert LemongeDepartment of Population, Policy and Practice, University College London Institute of Child Health, London, United Kingdom.
Hannah BristoweDepartment of Population, Policy and Practice, University College London Institute of Child Health, London, United Kingdom.
Suhail AslamDepartment of Population, Policy and Practice, University College London Institute of Child Health, London, United Kingdom.ORCID 0000-0003-4205-814X
Demetra KyprianouNorth Middlesex University Hospital NHS Trust, London, United Kingdom.
Eleni NastouliInfection, Immunity & Inflammation Department, University College London; Great Ormond Street Institute of Child Health, London, United Kingdom.
David GoldblattInfectious Disease Epidemiology Group, London School of Hygiene and Tropical Medicine, London, United Kingdom.ORCID 0000-0002-0769-5242
Katherine FieldingInfectious Disease Epidemiology Group, London School of Hygiene and Tropical Medicine, London, United Kingdom.
David A J MooreClinical Research Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
CONTACT team (field team)

Funding

Medical Research Council MR/R010161/1Medical Research Council MR/W016028/1Wellcome TrustWellcome Trust 210830/Z/18/Z
6 · The paper itself

Abstract

Historically SARS-CoV-2 secondary attack rates (SAR) have been based on PCR positivity on screening symptomatic contacts; this misses transmission events and identifies only symptomatic contacts who are PCR positive at the time of sampling. We used serology to detect the relative transmissibility of Alpha Variant of Concern (VOC) to non-VOC SARS-CoV-2 to calculate household secondary attack rates. We identified index patients diagnosed with Alpha and non-VOC SARS-CoV-2 across two London Hospitals between November 2020 and January 2021 during a prolonged and well adhered national lockdown. We completed a household seroprevalence survey and found that 61.8% of non-VOC exposed household contacts were seropositive compared to 82.1% of Alpha exposed household contacts. The odds of infection doubled with exposure to an index diagnosed with Alpha. There was evidence of transmission events in almost all households. Our data strongly support that estimates of SAR should include serological data to improve accuracy and understanding.

Indexed as

COVID-19SARS-CoV-2Communicable Disease ControlCross-Sectional StudiesHumansSeroepidemiologic Studies

Identifiers

PMID37093796
PMCPMC10124829

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.